Why would we give rivaroxaban and aspirin in superior mesmeric artery syndrome
Reading File
Quick answer: Superior mesenteric artery (SMA) syndrome involves compression of the SMA, which can lead to thrombus formation at the site of stenosis or turbulent flow. Rivaroxaban (a direct oral anticoagulant) prevents clot propagation, while aspirin (antiplatelet) reduces platelet aggregation at the arterial wall. Together, they address both the coagulation cascade and platelet-mediated thrombosis in the mesenteric circulation.
Searching sources...
Finding Sources
Finding Sources
Searching PubMed
superior mesenteric artery thrombosis anticoagulation antiplatelet
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
I now have enough textbook content to give a thorough answer. Let me also note a likely clarification: the question says "superior mesmeric artery syndrome" - this is almost certainly a typo for superior mesenteric artery (SMA) syndrome (also called Wilkie's syndrome, a mechanical compression of the duodenum). However, the clinical context of using rivaroxaban + aspirin fits much better with SMA thrombosis/occlusion (acute or chronic mesenteric ischemia due to SMA thrombus), not the mechanical compression syndrome per se. I'll address both possibilities.
Rivaroxaban + Aspirin in Superior Mesenteric Artery (SMA) Disease
First, a clarification: "SMA syndrome" technically refers to Wilkie's syndrome - a mechanical compression of the third part of the duodenum between the aorta and the SMA. This is primarily a mechanical/anatomical problem managed with nutritional support and positional maneuvers, and anticoagulants are not a standard treatment for it.
The use of rivaroxaban + aspirin makes clinical sense in the context of SMA thrombosis or chronic/acute mesenteric ischemia - which is what the question almost certainly refers to.
Why Aspirin?
Aspirin is an antiplatelet agent - it irreversibly inhibits COX-1, blocking thromboxane A2-mediated platelet aggregation.
In SMA disease:
- The underlying pathology is almost always atherosclerosis of the mesenteric vessels, shared with coronary, carotid, and peripheral arterial disease
- Platelet aggregation on atheromatous plaques initiates arterial thrombus formation
- Aspirin reduces this platelet-driven, arterial-type thrombosis
As stated in Goldman-Cecil Medicine: "Long-term care involves addressing underlying predisposing factors (e.g., smoking cessation, lipid-lowering therapy), lifelong therapy with aspirin in patients who undergo surgery." - Goldman-Cecil Medicine, p. 1507
Why Rivaroxaban?
Rivaroxaban is a direct oral anticoagulant (DOAC) - a direct factor Xa inhibitor. It blocks the common pathway of coagulation, preventing fibrin clot formation.
In SMA thrombosis, it is used because:
- Thrombus propagation prevention - once a thrombus forms in the SMA (especially following surgery, stenting, or embolectomy), rivaroxaban prevents extension of the clot downstream
- Embolic source treatment - SMA embolism often comes from a cardiac source (e.g., atrial fibrillation, mural thrombus after MI); rivaroxaban addresses the underlying cardioembolic mechanism
- Post-intervention anticoagulation - after thrombectomy, bypass, or endovascular stenting, anticoagulation is used to maintain graft/vessel patency
Why Both Together (Dual Antithrombotic Therapy)?
This combination - a DOAC + antiplatelet - is used specifically after endovascular stent placement in the SMA:
- Stents create a foreign surface that triggers both platelet activation (requiring antiplatelet cover) and coagulation cascade activation (requiring anticoagulation)
- Goldman-Cecil explicitly states: "dual antiplatelet therapy (usually with aspirin plus clopidogrel) in patients who undergo endovascular intervention" - however, in practice some centers use rivaroxaban + aspirin as an alternative dual-antithrombotic regimen following mesenteric stenting or in patients with concurrent high thrombotic risk (e.g., known AF + mesenteric stent)
The rationale mirrors that used after coronary or peripheral arterial stenting:
| Drug | Targets | Rationale |
|---|---|---|
| Aspirin | Platelet COX-1, TXA2 | Prevents platelet plug on atherosclerotic plaque/stent |
| Rivaroxaban (Factor Xa inhibitor) | Common coagulation pathway | Prevents fibrin thrombus propagation, treats embolic source |
Summary
- Aspirin addresses the arterial/atherosclerotic component - platelet-driven thrombus at the site of plaque rupture or stent
- Rivaroxaban addresses the coagulation/cardioembolic component - fibrin clot propagation or an embolic source like AF
- Together, they provide broader antithrombotic cover than either alone, which is warranted after SMA stenting or in patients with combined risk (atherosclerosis + hypercoagulable state)
- If the patient has SMA syndrome (Wilkie's) without thrombosis, these drugs are not indicated - the primary treatment is nutritional rehabilitation (nasojejunal feeding, prokinetics, and surgery in refractory cases)
Source: Goldman-Cecil Medicine International Edition, Chapter 129 - Mesenteric Vascular Diseases, pp. 1506-1509
Treatment of lewy body dementia
Reading File
Quick answer: Lewy body dementia (DLB) has no disease-modifying treatment. Management is symptomatic: cholinesterase inhibitors (rivastigmine/donepezil) for cognitive symptoms, levodopa for parkinsonism, and melatonin/clonazepam for REM sleep behavior disorder. Critically, antipsychotics are largely contraindicated due to severe neuroleptic sensitivity reactions.
Searching sources...
Finding Sources
Searching PubMed
"Lewy body dementia" treatment management
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
I now have comprehensive content from multiple textbooks. Here is the full answer:
Treatment of Dementia with Lewy Bodies (DLB)
There is no disease-modifying treatment for DLB. All current management is symptomatic, targeting the four core domains simultaneously: cognitive impairment, neuropsychiatric symptoms, motor (parkinsonian) features, and sleep disturbance.
1. Cognitive Symptoms
Cholinesterase inhibitors (AChEIs) are the first-line treatment.
DLB has profound cholinergic deficits (greater than in Alzheimer disease), which is why AChEIs show particularly good response.
| Drug | Dose | Notes |
|---|---|---|
| Donepezil | 10 mg/day (maintenance) | Does not exacerbate parkinsonian symptoms |
| Rivastigmine | 9.5 mg/24 hr patch (maintenance) | Also reduces delusions, hallucinations, and anxiety; has the most evidence in DLB |
| Galantamine | Alternative AChEI | Less studied in DLB specifically |
- British Association for Psychopharmacology guidelines list AChEIs as first choice for DLB, with memantine as second choice
- AChEIs may also help neuropsychiatric symptoms (hallucinations, agitation)
Goldman-Cecil Medicine, p. 1508; Maudsley Prescribing Guidelines 15e
2. Parkinsonian Motor Symptoms
Levodopa-carbidopa is used when gait or balance problems threaten safety.
- Start at levodopa/carbidopa 25/100 mg, 2 tablets 3× daily, titrating as tolerated
- Response is often partial and inconsistent - unlike idiopathic Parkinson disease
- Important caveat: Levodopa may worsen hallucinations and confusional states in DLB - this concern should not preclude a trial if motor symptoms threaten independence and safety
- The response to L-dopa may be inconsistent or transient
Adams and Victor's Principles of Neurology, 12e, p. 1079; Goldman-Cecil Medicine, p. 1508
3. Neuropsychiatric Symptoms (Hallucinations, Agitation, Psychosis)
This is the most challenging domain due to severe neuroleptic sensitivity - a defining feature of DLB.
CRITICAL CONTRAINDICATION: Conventional Antipsychotics
Typical (first-generation) antipsychotics are contraindicated in DLB. They cause:
- Dramatic worsening of parkinsonism
- Neuroleptic malignant syndrome
- Increased mortality
If antipsychotics are necessary (when AChEIs are insufficient):
Use low-dose atypical antipsychotics with the lowest extrapyramidal risk:
| Drug | Dose | Rationale |
|---|---|---|
| Quetiapine | 25-200 mg/day | Preferred by most movement disorder specialists; lowest EPS risk |
| Clozapine | 6.25-50 mg/day | Effective but requires blood monitoring (agranulocytosis risk) |
| Pimavanserin | Standard Parkinson psychosis dose | Selective 5-HT2A inverse agonist; no dopamine blockade; shown modest benefit for psychosis/hallucinations without worsening motor symptoms |
Note: Even atypical antipsychotics may carry elevated mortality risk in elderly dementia patients - the risk-benefit discussion with families is essential.
Adams and Victor's Principles of Neurology, 12e; Goldman-Cecil Medicine, p. 1508
4. REM Sleep Behavior Disorder (RBD)
RBD (acting out dreams, often with injury risk) is a core and early feature of DLB.
- Melatonin: 3-12 mg at bedtime - preferred first-line due to safety profile
- Clonazepam: 0.5-2 mg at bedtime - effective but sedating; use with caution in elderly
No controlled trials exist; these are consensus recommendations.
Goldman-Cecil Medicine, p. 1508
5. Autonomic Dysfunction
| Problem | Treatment | Caution |
|---|---|---|
| Orthostatic hypotension | Midodrine; fluid/salt loading | Fludrocortisone (less effective per clinical experience) |
| Urinary incontinence | Challenging - anticholinergic drugs risk worsening confusion | Minimize anticholinergics |
| Constipation | Laxatives, dietary fiber | - |
6. Depression
- SSRIs are preferred: sertraline 25-100 mg/day or citalopram 10-20 mg/day
- Do not use tricyclic antidepressants - heavy anticholinergic load worsens cognition and confusion
- Treatment of depression can substantially improve functioning
Goldman-Cecil Medicine, p. 1508
Summary Table
| Domain | First-Line | Second-Line / Notes |
|---|---|---|
| Cognition | AChEIs (rivastigmine, donepezil) | Memantine |
| Parkinsonism | Levodopa-carbidopa | Use cautiously (worsens psychosis) |
| Hallucinations/psychosis | Optimize AChEI dose | Quetiapine, clozapine, pimavanserin (AVOID typicals) |
| REM sleep disorder | Melatonin 3-12 mg | Clonazepam 0.5-2 mg |
| Orthostatic hypotension | Midodrine | Non-pharmacological measures |
| Depression | Sertraline, citalopram | Avoid tricyclics |
Recent evidence note: A 2024 meta-analysis (PMID 38439217) confirmed donepezil's benefit across multiple RCTs in DLB, supporting its use as first-line cognitive therapy. The overall management framework remains consistent with guidelines.
This is a shared conversation. Sign in to Orris to start your own chat.